These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18559610)

  • 1. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
    Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J; Zwiebel JA; Devine S; Byrd JC; Grever MR; Chan K; Marcucci G
    Clin Cancer Res; 2008 Jun; 14(12):3889-95. PubMed ID: 18559610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
    Klisovic RB; Blum W; Liu Z; Xie Z; Kefauver C; Huynh L; Zwiebel JA; Devine SM; Byrd JC; Grever MR; Chan KK; Marcucci G
    Leuk Lymphoma; 2014 Jun; 55(6):1332-6. PubMed ID: 24015841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
    Chen P; Aimiuwu J; Xie Z; Wei X; Liu S; Klisovic R; Marcucci G; Chan KK
    AAPS J; 2011 Mar; 13(1):131-40. PubMed ID: 21191677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
    Shibata SI; Doroshow JH; Frankel P; Synold TW; Yen Y; Gandara DR; Lenz HJ; Chow WA; Leong LA; Lim D; Margolin KA; Morgan RJ; Somlo G; Newman EM
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1149-55. PubMed ID: 19322566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
    Kirschbaum MH; Frankel P; Synold TW; Xie Z; Yen Y; Popplewell L; Chen R; Aljitawi O; Tuscano JM; Chan KK; Newman EM
    Leuk Lymphoma; 2016 Oct; 57(10):2307-14. PubMed ID: 26895565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
    Jin Y; Liu S; Yu B; Golan S; Koh CG; Yang J; Huynh L; Yang X; Pang J; Muthusamy N; Chan KK; Byrd JC; Talmon Y; Lee LJ; Lee RJ; Marcucci G
    Mol Pharm; 2010 Feb; 7(1):196-206. PubMed ID: 19852511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors.
    Malik L; Zwiebel A; Cooper J
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):533-539. PubMed ID: 30022224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
    Odenike OM; Larson RA; Gajria D; Dolan ME; Delaney SM; Karrison TG; Ratain MJ; Stock W
    Invest New Drugs; 2008 Jun; 26(3):233-9. PubMed ID: 18217206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
    Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
    Desai AA; Schilsky RL; Young A; Janisch L; Stadler WM; Vogelzang NJ; Cadden S; Wright JA; Ratain MJ
    Ann Oncol; 2005 Jun; 16(6):958-65. PubMed ID: 15824081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
    Stadler WM; Desai AA; Quinn DI; Bukowski R; Poiesz B; Kardinal CG; Lewis N; Makalinao A; Murray P; Torti FM
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):689-94. PubMed ID: 17569043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
    Leighl NB; Laurie SA; Chen XE; Ellis P; Shepherd FA; Knox JJ; Goss G; Burkes RL; Pond GR; Dick C; Yen Y; Zwiebel JA; Moore MJ
    J Thorac Oncol; 2009 Sep; 4(9):1163-9. PubMed ID: 19704337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
    Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
    J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
    Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
    J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase.
    Wei X; Dai G; Liu Z; Cheng H; Xie Z; Klisovic R; Marcucci G; Chan KK
    Drug Metab Dispos; 2008 Nov; 36(11):2227-33. PubMed ID: 18653746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
    Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
    Schimmer AD; Estey EH; Borthakur G; Carter BZ; Schiller GJ; Tallman MS; Altman JK; Karp JE; Kassis J; Hedley DW; Brandwein J; Xu W; Mak DH; LaCasse E; Jacob C; Morris SJ; Jolivet J; Andreeff M
    J Clin Oncol; 2009 Oct; 27(28):4741-6. PubMed ID: 19652057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2.
    Ferdinandi ES; Vassilakos A; Lee Y; Lightfoot J; Fitsialos D; Wright JA; Young AH
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):193-205. PubMed ID: 20886212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.